Texas Retina Dallas Research Team Recognized for Highest Site Enrollment Globally in Geographic Atrophy Clinical Trial
Under the leadership of Principal Investigator Dr. Ashkan M. Abbey, the Texas Retina Dallas research team was recently named the top enroller for Part I of the DFI18231 study, which is evaluating
read more
Offices Closed for Labor Day on 9/7/26
All Texas Retina offices will be closed on Monday, September 7, 2026, in observance of Labor Day. We wish everyone a safe and happy holiday weekend!
read more
Texas Retina’s Anna Brown Selected for Trials InSight Research Coordinator Executive Committee
Texas Retina Clinical Research Coordinator Anna Brown was recently selected by Trials InSight to serve on its new Research Coordinator Executive Committee. Trials InSight is a first-of-its-kind congress focused on the future
read more
Dr. Abbey and Texas Retina Dallas Research Team Recognized for Work on 4FRONT-2 Wet AMD Clinical Trial
4DMT recently recognized Dr. Ashkan Abbey and Texas Retina’s dedicated Dallas clinical research team for their contributions to advancing clinical research in genetic medicine through the 4FRONT-2 clinical trial. The 4FRONT-2 study
read more
National Retina Research Network Invites Dr. Shami to Discuss Current Study Protocols
The U.S.-based, federally funded DRCR Retina Network recently invited Texas Retina’s Michel J. Shami, MD, to provide investigators with updates on three of the network’s current studies: Protocol AF: A randomized trial
read more
Monitoring Age-related Macular Degeneration at Home
As the leading cause of vision loss in older adults, age-related macular degeneration (AMD) is the most common reason patients are referred to Texas Retina. It happens when the central part of
read more
New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of many retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision. That is why
read more
Texas Retina First in the US to Randomize a Patient in the i-SIGHT2 Bioelectric Therapy for Dry AMD Clinical Trial
The i-SIGHT2 pivotal clinical trial is evaluating the investigational i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration (AMD), and on July 1, 2026, Texas Retina’s Patrick D.
read more Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more
Getting to Know Rene Y. Choi, MD, PhD
Texas Retina was fortunate to have board-certified ophthalmologist and retina specialist Rene Choi, MD, PhD, join our team in September 2020, and he currently cares for patients in our Denton and Frisco
read more